Short answer
Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 8.01 (Other Events). FDA Fast Track designation granted to XPro™ for early Alzheimer’s disease treatment.
Inmune Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Fast Track designation granted to XPro™ for early Alzheimer’s disease treatment
- XPro™ described as INmune Bio’s first-in-class selective soluble TNF inhibitor
- Regulatory designation may accelerate FDA interactions and development timelines
- Press release dated May 14, 2026, provides additional program details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inmune Bio, Inc. 8-K filings
Get the next INMB 8-K as it lands
Follow INMB for push alerts, or ask the research agent what this filing means.